Platelets, extracellular vesicles and coagulation in pulmonary arterial hypertension
暂无分享,去创建一个
B. Kevane | F. Ní Áinle | S. Gaine | P. Maguire | S. Cullivan | L. Weiss | Claire A. Murphy | B. Mccullagh | S. Comer | B. McCullagh
[1] M. Humbert,et al. Sotatercept for the Treatment of Pulmonary Arterial Hypertension. , 2021, The New England journal of medicine.
[2] A. Torbicki,et al. Prostacyclin Analogues Inhibit Platelet Reactivity, Extracellular Vesicle Release and Thrombus Formation in Patients with Pulmonary Arterial Hypertension , 2021, Journal of clinical medicine.
[3] Yusuke Kodama,et al. Fibrinolytic markers could be useful predictors of severity in patients with pulmonary arterial hypertension: a retrospective study , 2021, Thrombosis Journal.
[4] S. Orfanos,et al. Coagulation Profiles of Pulmonary Arterial Hypertension Patients, Assessed by Non-Conventional Hemostatic Tests and Markers of Platelet Activation and Endothelial Dysfunction , 2020, Diagnostics.
[5] J. Münch,et al. Inhaled and systemic heparin as a repurposed direct antiviral drug for prevention and treatment of COVID-19. , 2020, Clinical medicine.
[6] A. Winnicka,et al. Platelets Extracellular Vesicles as Regulators of Cancer Progression—An Updated Perspective , 2020, International journal of molecular sciences.
[7] A. Ogawa,et al. Increased levels of platelet-derived microparticles in pulmonary hypertension. , 2020, Thrombosis research.
[8] R. Dweik,et al. Platelet Glycolytic Metabolism Correlates with Hemodynamic Severity in Pulmonary Arterial Hypertension. , 2020, American journal of physiology. Lung cellular and molecular physiology.
[9] R. Freishtat,et al. Platelets and platelet extracellular vesicles in hemostasis and sepsis , 2019, Journal of Investigative Medicine.
[10] D. Salvail,et al. NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension , 2019, BMC Pulmonary Medicine.
[11] L. Denby,et al. Extracellular vesicle cross-talk between pulmonary artery smooth muscle cells and endothelium during excessive TGF-β signalling: implications for PAH vascular remodelling , 2019, Cell Communication and Signaling.
[12] H. Ghofrani,et al. Enhanced circulating levels of CD3 cells-derived extracellular vesicles in different forms of pulmonary hypertension , 2019, Pulmonary circulation.
[13] J. Kamińska,et al. Mean Platelet Volume (MPV): New Perspectives for an Old Marker in the Course and Prognosis of Inflammatory Conditions , 2019, Mediators of inflammation.
[14] D. Badesch,et al. Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report , 2019, Chest.
[15] G. Simonneau,et al. An overview of the 6th World Symposium on Pulmonary Hypertension , 2019, European Respiratory Journal.
[16] M. Humbert,et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives , 2019, European Respiratory Journal.
[17] N. Stockbridge,et al. Clinical trial design and new therapies for pulmonary arterial hypertension , 2019, European Respiratory Journal.
[18] Jing Xu,et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines , 2018, Journal of Extracellular Vesicles.
[19] E. Lefrançais,et al. Platelet Biogenesis in the Lung Circulation. , 2018, Physiology.
[20] S. Rich,et al. Are anticoagulants still indicated in pulmonary arterial hypertension? , 2018, Pulmonary circulation.
[21] M. Khan,et al. Is Anticoagulation Beneficial in Pulmonary Arterial Hypertension?: A Systematic Review and Meta-Analysis , 2018, Circulation. Cardiovascular quality and outcomes.
[22] M. Carcao,et al. Idiopathic pulmonary arterial hypertension – a unrecognized cause of high‐shear high‐flow haemostatic defects (otherwise referred to as acquired von Willebrand syndrome) in children , 2018, British journal of haematology.
[23] D. Kenny,et al. Dual endothelin‐1 receptor antagonism attenuates platelet‐mediated derangements of blood coagulation in Eisenmenger syndrome , 2018, Journal of thrombosis and haemostasis : JTH.
[24] M. MacLean. The serotonin hypothesis in pulmonary hypertension revisited: targets for novel therapies (2017 Grover Conference Series) , 2018, Pulmonary circulation.
[25] A. Stamatoullas,et al. Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial. , 2018, The Lancet. Haematology.
[26] C. Strange,et al. Use of multitarget tyrosine kinase inhibitors to attenuate platelet-derived growth factor signalling in lung disease , 2017, European Respiratory Review.
[27] M. Gladwin,et al. Platelets from pulmonary hypertension patients show increased mitochondrial reserve capacity. , 2017, JCI insight.
[28] R. Linhardt,et al. Heparin: Past, Present, and Future , 2016, Pharmaceuticals.
[29] Dave P. Miller,et al. Response to Letter Regarding Article, "Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL)". , 2016, Circulation.
[30] J. McClure,et al. MicroRNA-143 Activation Regulates Smooth Muscle and Endothelial Cell Crosstalk in Pulmonary Arterial Hypertension. , 2015, Circulation research.
[31] S. Harari,et al. Pulmonary hypertension in patients with chronic myeloproliferative disorders , 2015, European Respiratory Review.
[32] M. Humbert,et al. The molecular targets of approved treatments for pulmonary arterial hypertension , 2015, Thorax.
[33] Zhi-Hong Liu,et al. Platelet distribution width and mean platelet volume in idiopathic pulmonary arterial hypertension. , 2015, Heart, lung & circulation.
[34] C. Hales,et al. Heparin reduces overcirculation-induced pulmonary artery remodeling through p38 MAPK in piglet. , 2015, The Annals of thoracic surgery.
[35] R. Phipps,et al. Thrombosis, platelets, microparticles and PAH: more than a clot. , 2014, Drug discovery today.
[36] H. Ghofrani,et al. Selexipag for the Treatment of Pulmonary Arterial Hypertension. , 2014, The New England journal of medicine.
[37] K. Nickel,et al. Thrombin Has Biphasic Effects on the Nitric Oxide-cGMP Pathway in Endothelial Cells and Contributes to Experimental Pulmonary Hypertension , 2013, PloS one.
[38] H. Ghofrani,et al. Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension: Results of the Randomized IMPRES Study , 2013, Circulation.
[39] A. Weyrich,et al. Platelets in lung biology. , 2013, Annual review of physiology.
[40] M. Humbert,et al. Cellular microparticles in the pathogenesis of pulmonary hypertension , 2012, European Respiratory Journal.
[41] P. Tuinman,et al. Nebulized anticoagulants for acute lung injury - a systematic review of preclinical and clinical investigations , 2012, Critical Care.
[42] K. Fukuda,et al. Platelet level as a new prognostic factor for idiopathic pulmonary arterial hypertension in the era of combination therapy. , 2012, Circulation journal : official journal of the Japanese Circulation Society.
[43] A. Mogilner,et al. Microtubule and cortical forces determine platelet size during vascular platelet production , 2012, Nature Communications.
[44] A. Chu. Tissue Factor, Blood Coagulation, and Beyond: An Overview , 2011, International journal of inflammation.
[45] A. Simon,et al. Microparticles, Vascular Function, and Atherothrombosis , 2011, Circulation research.
[46] R. Barr,et al. Randomized Clinical Trial of Aspirin and Simvastatin for Pulmonary Arterial Hypertension: ASA-STAT , 2011, Circulation.
[47] E. Varol,et al. Platelet Indices in Patients With Pulmonary Arterial Hypertension , 2011, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
[48] A. Chaouat,et al. Calibrated automated thrombography demonstrates hypercoagulability in patients with idiopathic pulmonary arterial hypertension. , 2010, Thrombosis research.
[49] J. Hartwig,et al. Cytoskeletal mechanics of proplatelet maturation and platelet release , 2010, The Journal of cell biology.
[50] H. Farber,et al. Use of selective serotonin reuptake inhibitors and outcomes in pulmonary arterial hypertension. , 2010, Chest.
[51] R. Andriantsitohaina,et al. Circulating microparticles from pulmonary hypertensive rats induce endothelial dysfunction. , 2010, American journal of respiratory and critical care medicine.
[52] D. Laskin,et al. Threshold size for optimal passive pulmonary targeting and retention of rigid microparticles in rats. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[53] J. Hansen,et al. Soluble Guanylate Cyclase Agonists Inhibit Expression and Procoagulant Activity of Tissue Factor , 2009, Arteriosclerosis, thrombosis, and vascular biology.
[54] H. Kantarjian,et al. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. , 2009, Blood.
[55] J. Thachil. The lung megakaryocytes and pulmonary fibrosis in systemic sclerosis. , 2009, Medical hypotheses.
[56] A. Weyrich,et al. Amicus or adversary: platelets in lung biology, acute injury, and inflammation. , 2009, American journal of respiratory cell and molecular biology.
[57] W. Grossman,et al. Circulating endothelial microparticle levels predict hemodynamic severity of pulmonary hypertension. , 2008, American journal of respiratory and critical care medicine.
[58] J. Freyssinet,et al. Procoagulant membrane microparticles correlate with the severity of pulmonary arterial hypertension. , 2008, American journal of respiratory and critical care medicine.
[59] Christine M. Miller,et al. Plexiform-like lesions and increased tissue factor expression in a rat model of severe pulmonary arterial hypertension. , 2007, American journal of physiology. Lung cellular and molecular physiology.
[60] H. Klemm,et al. Heparins Increase Endothelial Nitric Oxide Bioavailability by Liberating Vessel-Immobilized Myeloperoxidase , 2006, Circulation.
[61] D. Newby,et al. Sildenafil potentiates nitric oxide mediated inhibition of human platelet aggregation. , 2005, Biochemical and biophysical research communications.
[62] M. Humbert,et al. Serotonin-Induced Smooth Muscle Hyperplasia in Various Forms of Human Pulmonary Hypertension , 2004, Circulation research.
[63] F. Massó,et al. Endothelin-1 and functional tissue factor: a possible relationship with severity in primary pulmonary hypertension , 2003, Heart and Vessels.
[64] N. Ozer,et al. Thrombopoietin inside the pulmonary vessels in patients with and without pulmonary hypertension. , 2002, Platelets.
[65] W. Seeger,et al. Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension. , 2002, American heart journal.
[66] M. Humbert,et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. , 2001, The Journal of clinical investigation.
[67] M. Humbert,et al. Pathobiology of pulmonary hypertension. The role of platelets and thrombosis. , 2001, Clinics in chest medicine.
[68] F. Sakamaki,et al. Increased Plasma P-Selectin and Decreased Thrombomodulin in Pulmonary Arterial Hypertension Were Improved by Continuous Prostacyclin Therapy , 2000, Circulation.
[69] M. Humbert,et al. Improvement of von Willebrand Factor Proteolysis After Prostacyclin Infusion in Severe Pulmonary Arterial Hypertension , 2000, Circulation.
[70] D. Langleben,et al. Heparin-like molecules inhibit pulmonary vascular pericyte proliferation in vitro. , 2000, American journal of physiology. Lung cellular and molecular physiology.
[71] C. Philipp,et al. Platelet production in the pulmonary capillary bed: new ultrastructural evidence for an old concept. , 2000, The American journal of pathology.
[72] M. Hoeper,et al. Plasma coagulation profiles in patients with severe primary pulmonary hypertension. , 1998, The European respiratory journal.
[73] R. Altman,et al. Coagulation and fibrinolytic parameters in patients with pulmonary hypertension , 1996, Clinical cardiology.
[74] J. Launay,et al. Increased plasma serotonin in primary pulmonary hypertension. , 1995, The American journal of medicine.
[75] P. Mulder,et al. Thrombotic lesions in primary plexogenic arteriopathy. Similar pathogenesis or complication? , 1993, Chest.
[76] B. Groves,et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. , 1992, The New England journal of medicine.
[77] A. Jaffe,et al. Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension. , 1990, Circulation.
[78] B. Groves,et al. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. , 1989, Circulation.
[79] R. Virmani,et al. Heterogeneity of pathologic lesions in familial primary pulmonary hypertension. , 1988, The American review of respiratory disease.
[80] V. Fuster,et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. , 1984, Circulation.
[81] M. Mcgoon,et al. Thrombocytopenia independently predicts death in idiopathic PAH , 2019, Heart & lung : the journal of critical care.
[82] Marvin Kajy. Anticoagulation and Survival in Pulmonary Arterial Hypertension Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) , 2014 .
[83] R. Flaumenhaft. Chapter 18 – Platelet Secretion , 2013 .
[84] S. Smyth,et al. Interactions Between Platelets, Leukocytes, and the Endothelium , 2013 .
[85] J. D. de Lemos,et al. Hemodynamics and epoprostenol use are associated with thrombocytopenia in pulmonary arterial hypertension. , 2009, Chest.
[86] E. Young. The anti-inflammatory effects of heparin and related compounds. , 2008, Thrombosis research.
[87] J. Hartwig,et al. Chapter 2 – Megakaryocyte Development and Platelet Formation , 2007 .
[88] R. Barst,et al. Endothelin receptor antagonists for pulmonary arterial hypertension. , 2005, The Cochrane database of systematic reviews.